Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 2 | Health Economics Review

Fig. 2

From: Cost-effectiveness of the addition of sintilimab as a first-line therapy for locally advanced or metastatic oesophageal squamous cell carcinoma: a Chinese healthcare system perspective

Fig. 2

(A) progression-free survival (PFS) for patients in the ORIENT-15 trial; (B) progression-free survival (PFS) for the model-estimated data; (C) OS for patients in the ORIENT-15 trial; (D) overall survival (OS) for the model-estimated data; (E) in terms of the median OS and PFS, the simulated results were consistent with the empirical data from the ORIENT-15 trial; Sin-Che, sintilimab-chemotherapy; Pla-Che, placebo-chemotherapy; OS, overall survival; PFS, progression-free survival

Back to article page

Health Economics Review

ISSN: 2191-1991

Contact us